Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
Voyager Therapeutics, Inc. (VYGR)
|
Add to portfolio |
|
|
|
| Price: |
$2.99
| | Metrics |
| OS: |
43.9
|
M
| |
48
|
% ROE
|
| Market cap: |
$131
|
M
| |
227
|
% ROIC
|
|
Net cash:
|
$273
|
M
| |
$6.21
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
$87.3
|
M
| |
-1.6
|
x EV/EBIT
|
| EPS |
$2.26
| |
1.3
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 40.9 | 37.4 | 171.1 | 104.4 | 7.6 | 10.1 | 14.2 | 17.3 |
| Revenue growth | 9.3% | -78.1% | 63.9% | 1270.1% | -24.8% | -28.7% | -18.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 40.9 | 37.4 | 171.1 | 104.4 | 7.6 | 10.1 | 14.2 | 17.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 60.8 | 73.8 | 108.8 | 119.7 | 64.9 | 62.3 | 42.2 | 27.7 |
| General and administrative | 31.0 | 37.2 | 35.0 | 36.3 | 33.8 | 19.7 | 13.3 | 9.9 |
| EBIT | -50.8 | -73.6 | 27.4 | -51.7 | -91.1 | -71.9 | -41.3 | -20.3 |
| EBIT margin | -124.3% | -196.8% | 16.0% | -49.5% | -1195.6% | -709.1% | -290.4% | -116.8% |
| Pre-tax income | -46.4 | -71.2 | 36.7 | -43.6 | -88.5 | -70.7 | -40.1 | -29.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | 0.1 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | | 0.0% |
| Net income | -46.4 | -71.2 | 36.7 | -43.6 | -88.3 | -70.7 | -40.2 | -38.3 |
| Net margin | -113.4% | -190.3% | 21.5% | -41.8% | -1158.8% | -697.6% | -282.7% | -220.9% |
| |
| Diluted EPS | ($1.21) | ($1.89) | $0.98 | ($1.21) | ($2.75) | ($2.64) | ($1.59) | ($9.14) |
| Shares outstanding (diluted) | 38.4 | 37.7 | 37.3 | 35.9 | 32.1 | 26.8 | 25.3 | 4.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|